The AI Factor: Why Cash Still Flows To European Biotech Startups

Putting the Tech In Bio: Why Cash Still Flows To European Biotech Startups

Amid ongoing concerns about declining VC funding in the United Kingdom, Biotech startups have been doing rather well. According to the U.K. Bio Association, businesses working in the sector raised £563 million in venture capital and public funding in the three months to September. Following a sluggish start to the year, the Association predicts the industry is on course to exceed the levels of funding seen in 2022. Meanwhile, KPMG’s latest U.K. Venture Pulse report notes that Biotech – along with AI and climate tech – is set to dominate the investment agenda.

→ Continue reading at Forbes - Startups

More from author

Related posts


Latest posts

Workers are seeing how AI could change our jobs

Every day in the workplace, people are discovering that artificial intelligence has the potential to change our jobs and our lives — for...

20 years ago, the supersonic passenger jet Concorde flew for the last time

Enlarge this image A British Airways Concorde takes off from London's...

The tug-of-war is on between deal-hungry Black Friday shoppers and retailers wary of throw-away prices | CNN Business

New York CNN  —  Let the shopping games begin. Deal-hunters headed to their favorite stores in person...